West Oak Capital LLC Has $163,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

West Oak Capital LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1,318.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,483 shares of the company’s stock after purchasing an additional 2,308 shares during the period. West Oak Capital LLC’s holdings in AstraZeneca were worth $163,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in AZN. McClarren Financial Advisors Inc. grew its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in AstraZeneca in the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP bought a new stake in AstraZeneca during the third quarter worth approximately $28,000. Groupama Asset Managment grew its holdings in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of AstraZeneca in the third quarter valued at approximately $45,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock traded up $0.43 during trading hours on Friday, hitting $67.01. The stock had a trading volume of 5,671,171 shares, compared to its average volume of 4,304,024. The company has a market cap of $207.77 billion, a PE ratio of 32.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a 50-day moving average of $66.20 and a two-hundred day moving average of $75.01.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the business earned $0.87 EPS. The firm’s revenue was up 18.0% on a year-over-year basis. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

AZN has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.